Zacks: Analysts Expect BioVie Inc. (NASDAQ:BIVI) Will Announce Earnings of -$0.52 Per Share

Wall Street brokerages expect BioVie Inc. (NASDAQ:BIVIGet Rating) to report ($0.52) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for BioVie’s earnings. The lowest EPS estimate is ($0.71) and the highest is ($0.33). The business is scheduled to announce its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that BioVie will report full-year earnings of ($2.15) per share for the current year, with EPS estimates ranging from ($3.08) to ($1.22). For the next year, analysts anticipate that the business will report earnings of ($1.89) per share, with EPS estimates ranging from ($2.01) to ($1.76). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that cover BioVie.

BioVie (NASDAQ:BIVIGet Rating) last issued its quarterly earnings results on Tuesday, February 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.41) by $0.19.

A number of equities research analysts recently weighed in on BIVI shares. Zacks Investment Research downgraded BioVie from a “buy” rating to a “hold” rating in a research report on Tuesday, February 1st. Oppenheimer started coverage on BioVie in a research report on Monday, March 14th. They set an “outperform” rating and a $9.00 target price on the stock. Finally, B. Riley decreased their target price on BioVie from $27.00 to $18.00 in a research report on Monday, January 24th.

Shares of NASDAQ:BIVI traded down $0.35 during midday trading on Thursday, hitting $3.98. The company’s stock had a trading volume of 19,110 shares, compared to its average volume of 50,649. The stock’s 50 day simple moving average is $3.83 and its 200 day simple moving average is $4.72. BioVie has a fifty-two week low of $2.52 and a fifty-two week high of $23.86. The company has a current ratio of 7.01, a quick ratio of 7.01 and a debt-to-equity ratio of 0.69.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. swisspartners Ltd. boosted its holdings in BioVie by 45.0% during the third quarter. swisspartners Ltd. now owns 80,521 shares of the company’s stock valued at $542,000 after purchasing an additional 25,000 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in BioVie by 90.3% during the third quarter. Renaissance Technologies LLC now owns 53,100 shares of the company’s stock valued at $355,000 after purchasing an additional 25,200 shares in the last quarter. Geode Capital Management LLC boosted its holdings in BioVie by 49.7% during the fourth quarter. Geode Capital Management LLC now owns 28,368 shares of the company’s stock valued at $127,000 after purchasing an additional 9,415 shares in the last quarter. State Street Corp acquired a new stake in BioVie during the fourth quarter valued at approximately $67,000. Finally, Susquehanna International Group LLP acquired a new stake in BioVie during the fourth quarter valued at approximately $48,000. 5.96% of the stock is currently owned by institutional investors.

About BioVie (Get Rating)

BioVie Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease.

Further Reading

Get a free copy of the Zacks research report on BioVie (BIVI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BioVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioVie and related companies with MarketBeat.com's FREE daily email newsletter.